Patient variables that predict atypical cytology by nipple duct lavage

Cancer

Volumn 109, Issue 7, 2007, Pages 1247-1254

  Bushnaq, Zinaida I ^a   Ashfaq, Raheela ^a   Leitch, A Marilyn ^a   Euhus, David ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Atypia; Breast cancer risk; Nipple aspirate fluid; Nipple duct lavage

Indexed keywords

ADULT; ARTICLE; ASPIRATION; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANNULATION; CYTOLOGY; CYTOPATHOLOGY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LAVAGE; MAJOR CLINICAL STUDY; NIPPLE DUCT LAVAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYTODIAGNOSIS; FEMALE; HUMANS; IRRIGATION; MASS SCREENING; MIDDLE AGED; NIPPLES; PRECANCEROUS CONDITIONS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 33947532716     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22538     Document Type: Article

References (28)

1. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006; 56:168-183.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
3. Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. J Clin Oncol. 2002;20:9-16.
4. Kisinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137:59-69.
5. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical technology assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999;17:1939-1955.
6. Levine M, Moutquin JM, Walton R, Feightner J, Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 2001;164:1681-1690.
7. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580-585.
8. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93:358-366.
9. Dupont WD, Pari FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-1265.
10. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000;92:1217-1227.
11. Wrensch MR, Petrakis NL, King EB, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 1992;135:130-141.
12. Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst. 2001;93:1791-1798.
13. O'Shaughnessy JA, Ljung BM, Dooley WC, et al. Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer. 2002;94:292-298.
14. Zalles CM, Kimler BF, Simonsen M, Clark JL, Metheny T, Fabian CJ. Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer. Breast Cancer Res Treat. 2006;97:191-197.
15. Dooley WC, Ljung B, Veronesi U, et al. Ductal lavage for the detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001;93:1624-1632.
16. Morrow M, Vogel V, Ljung BM, O'Shaughnessy JA. Evaluation and management of the woman with an abnormal ductal lavage. J Am Coll Surg. 2002;194:648-656.
17. Sharma P, Klemp JR, Simonsen M, et al. Failure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimens. Breast Cancer Res Treat. 2004; 87:59-64.
18. Johnson-Maddux A, Ashfaq R, Nafthalis EZ, Leitch AM, Hoover S, Euhus DM. Patient and duct selection for nipple duct lavage. Am J Surg. 2004;188:390-394.
19. Kurian AW, Mills MA, Jaffee M, et al. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14:1082-1089.
20. Euhus D. Understanding mathematical models for breast cancer risk assessment. Breast J. 2001;7:224-232.
21. Khan SA, Wiley EL, Rodriguez N, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst. 2004;96:1510-1517.
22. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer. 1997;76:494-501.
23. Wrensch MR, Petrakis NL, Gruenke LD, et al. Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res Treat. 1990;15:39-51.
24. Wrensch MR, Petrakis NL, King EB, Lee MM, Miike R. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol. 1993;137:829-833.
25. Higgins SA, Matloff ET, Rimm DL, Dziura J, Haffty BG, King BL. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res. 2005;7:R1017-R1022.
26. Rose DP, Lahti H, Laakso K, Kettunen K, Wynder EL. Serum and breast duct fluid prolactin and estrogen levels in healthy Finnish and American women and patients with fibrocystic disease. Cancer. 1986;57:1550-1554.
27. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for while females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
28. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541-1548.